18 completed. 18 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 18 |
| Phase 2 | 4 | Completed 4 |
Follow Rapamycin: new trials by email Literature Review of Rapamycin trials Research Report on Rapamycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Gerotherapeutic Interventions for Healthspan Improvement Rapamycin, Naltrexone, Metformin - Healthspan Improvement, Aging | Phase 3 | Completed | AgelessRx | 26 | 2025-07-23 | 2026-10-30 |
| Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex rapamycin, placebo - Facial Angiofibroma, Tuberous Sclerosis | Phase 2 / Phase 3 | Completed | Dermatology Specialties Limited Partnership | 107 | 2019-07-28 | 2023-09-08 |
| Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome Sirolimus - Sturge-Weber Syndrome | Phase 2 / Phase 3 | Completed | Anne Comi, MD | 10 | 2017-01-01 | 2021-11-01 |
| Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI) - Complication of Renal Dialysis, End Stage Renal Disease | Phase 3 | Completed | Vascular Therapies, Inc. | 269 | 2015-11-01 | 2025-10-09 |
| Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Rapamycin, Placebo - Inclusion Body Myositis (IBM) | Phase 2 / Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 44 | 2015-07-15 | 2025-09-02 |
| Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis Rapamycin, Calcitriol, Rapamycin-calcitriol combination - Facial Angiofibroma | Phase 3 | Completed | National Taiwan University Hospital | 52 | 2013-09-05 | 2017-05-04 |
| Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations Sirolimus - Cardiovascular Abnormalities | Phase 3 | Completed | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 19 | 2012-05-01 | 2016-04-14 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Completed | Fred Hutchinson Cancer Center | 174 | 2010-11-01 | 2026-04-30 |
| Topical Rapamycin for Fibrofolliculomas Rapamycin, placebo - Birt-Hogg-Dubé Syndrome | Phase 3 | Completed | Maastricht University Medical Center | 19 | 2010-01-01 | 2012-03-08 |
| Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma Sirolimus, Methotrexate, Tacrolimus - Non-hodgkin Lymphoma, Hodgkin Lymphoma | Phase 3 | Completed | Dana-Farber Cancer Institute | 139 | 2009-06-01 | 2019-02-01 |
| Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission thiotepa, cyclophosphamide, tacrolimus - B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission | Phase 3 | Completed | Children's Oncology Group | 146 | 2007-03-01 | 2019-08-07 |
| Efficacy and Safety of Sirolimus in LAM Sirolimus, Placebo - Lymphangioleiomyomatosis | Phase 3 | Completed | University of Cincinnati | 89 | 2006-12-01 | 2023-11-02 |
| Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Tacrolimus, Methotrexate, Sirolimus - Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute | Phase 3 | Completed | Medical College of Wisconsin | 304 | 2006-11-01 | 2023-01-04 |
| Islet Transplantation in Type 1 Diabetes Allogeneic Pancreatic Islet Cells, Antithymocyte Globulin, Sirolimus - Type 1 Diabetes Mellitus | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 48 | 2006-10-01 | 2019-07-17 |
| TBI Dose De-escalation for Fanconi Anemia Cyclophosphamide, Fludarabine, Total Body Irradiation - Fanconi Anemia | Phase 2 / Phase 3 | Completed | Masonic Cancer Center, University of Minnesota | 83 | 2006-05-18 | 2021-11-24 |
| Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients Cyclosporine, Daclizumab, Mycophenoate Mofetil - Renal Transplantation | Phase 3 | Completed | Hoffmann-La Roche | 237 | 2004-11-01 | 2016-02-19 |
| TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients rapamycin, ciclosporine, tacrolimus - Skin Cancer, Kidney Transplantation | Phase 3 | Completed | Hospices Civils de Lyon | 77 | 2004-04-01 | 2025-12-26 |
| Pre Transplant Rapamycin Treatment in Islet Transplantation Alone rapamycin - Diabetes Mellitus, Type 1 | Phase 3 | Completed | IRCCS San Raffaele | 11 | 2001-10-01 | 2010-02-02 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Diabetes Mellitus, Type 1 (2) · Graft vs Host Disease (2) · Hodgkin Disease (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Tuberous Sclerosis (2) · Arteriovenous Fistula (1) · Birt-Hogg-Dube Syndrome (1) · Carcinoma, Squamous Cell (1) · Cardiovascular Abnormalities (1) · Cognitive Dysfunction (1) · Fanconi Anemia (1) · Hematologic Neoplasms (1)
AgelessRx (1) · Anne Comi, MD (1) · Children's Oncology Group (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Dana-Farber Cancer Institute (1) · Dermatology Specialties Limited Partnership (1) · Fred Hutchinson Cancer Center (1) · Hoffmann-La Roche (1) · Hospices Civils de Lyon (1) · IRCCS San Raffaele (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Maastricht University Medical Center (1) · Masonic Cancer Center, University of Minnesota (1) · Medical College of Wisconsin (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (11) · France (4) · Canada (3) · Australia (2) · Belgium (1) · Czechia (1) · Denmark (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Netherlands (1) · New Zealand (1) · Serbia (1) · Slovakia (1)
Ali Naji, PhD (1) · Andrew Posselt, MD, PhD (1) · Anne M Comi, M.D. (1) · Antonio Secchi, MD (1) · Bernhard Hering, MD (1) · Brenda Sandmaier (1) · Camillo Ricordi, MD (1) · Francis X McCormack, MD (1) · Ioana Stanescu (1) · James Shapiro, MD, PhD (1) · Jenell Decker, MD (1) · Laurence Boon, MD, PhD (1) · Margaret L MacMillan, M.D. (1) · Mary Horowitz, MD (1)
PMID 15061852, PMID 15753371, PMID 21046356, PMID 21180274, PMID 21410393, PMID 22830463, PMID 23438305, PMID 23630300, PMID 24159565, PMID 24497539, PMID 24910976, PMID 24982504, PMID 25629445, PMID 25862561, PMID 25979023, PMID 26729448, PMID 26799509, PMID 27208344, PMID 27465220, PMID 29563196, PMID 29654388, PMID 30016177, PMID 30846465, PMID 31248843, PMID 32499241, PMID 36927115, PMID 37463422, PMID 38273639
P01CA018029 (1), P30CA015704 (1), U01HL069294 (1), U10CA098543 (1), U54NS065705 (1), U54RR019498 (1)